| Literature DB >> 35226674 |
Chia-En Lien1, Yiing-Jenq Chou2,3, Yi-Jung Shen4, Theodore Tsai5, Nicole Huang4.
Abstract
BACKGROUND: Antibiotic treatment for dengue is likely considerable and potentially avoidable but has not been well characterized. This study aimed to assess antibiotic prescribing for confirmed dengue cases in outpatient and inpatient settings and to identify associated patient, physician and contextual factors.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35226674 PMCID: PMC8884547 DOI: 10.1371/journal.pntd.0010198
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Patient characteristics and medical utilization patterns among 57,301 confirmed adult dengue patients, Taiwan, 2008–2015.
| Patients with dengue (N = 57,301) | |
|---|---|
| N (%) | |
|
| |
| No | 6,079 (10.6) |
| Yes | 51,222 (89.4) |
|
| |
| Age, y | |
| 18–45 | 22,866 (39.9) |
| 45–64 | 22,092 (38.6) |
| ≥65 | 12,343 (21.5) |
| Sex | |
| Male | 28,040 (48.9) |
| Female | 29,261 (51.1) |
| SES | |
| < $30,000 NTD | 21,871 (38.2) |
| ≥ $30,000 NTD | 19,391 (33.8) |
| Others | 16,039 (28.0) |
| Major comorbidities | |
| No | 53,310 (93.0) |
| Yes | 3,991 (7.0) |
| Fever | |
| No | 4,839 (8.4) |
| Yes | 52,462 (91.6) |
|
| |
| Any antibiotics prescribed | |
| No | 43,190 (75.4) |
| Yes | 14,111 (24.6) |
| Outpatient utilization | |
| No | 1,263 (2.2) |
| Yes | 56,038 (97.8) |
| Outpatient utilization before confirmation | |
| No | 17,501 (30.5) |
| Yes | 39,800 (69.5) |
| Outpatient utilization after confirmation | |
| No | 9,189 (16.0) |
| Yes | 48,112 (84.0) |
| Hospitalization | |
| No | 38,003 (66.3) |
| Yes | 19,298 (33.7) |
| Hospitalization before confirmation | |
| No | 54,121 (94.5) |
| Yes | 3,180 (5.5) |
| Hospitalization after confirmation | |
| No | 41,059 (71.7) |
| Yes | 16,242 (28.3) |
| ICU utilization | |
| No | 1,041 (5.4) |
| Yes | 18,257 (94.6) |
$30 NTD ≌ $1 US dollar.
Abbreviation: SES, socioeconomic status; ICU, intensive care unit.
Outpatient antibiotic use for confirmed dengue by patient and physician characteristics, in pre- and post- dengue diagnosis visits, Taiwan, 2008–2015.
| Total | Pre-dengue confirmation | Post- dengue confirmation | ||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotics use | Antibiotics use | Antibiotics use | ||||||
| N (%) | % | N (%) | % | P | N (%) | % | P | |
|
|
|
|
|
|
|
| ||
|
| < .01 | < .01 | ||||||
| No | 19,186 (10.1) | 9.3% | 11,087 (14.7) | 11.3% | 8,099 (7.1) | 6.5% | ||
| Yes | 170,324 (89.9) | 5.8% | 64,085 (85.3) | 8.9% | 106,239 (92.9) | 3.9% | ||
|
| ||||||||
| Age, y | < .01 | < .01 | ||||||
| 18–45 | 72,612 (38.3) | 6.7% | 27,996 (37.2) | 10.6% | 44,616 (39.0) | 4.3% | ||
| 45–64 | 75,768 (40.0) | 5.7% | 29,546 (39.3) | 8.7% | 46,222 (40.4) | 3.7% | ||
| ≥65 | 41,130 (21.7) | 5.9% | 17,630 (23.5) | 8.0% | 23,500 (20.6) | 4.4% | ||
| Sex | .02 | < .01 | ||||||
| Male | 90,401 (47.7) | 5.7% | 35,237 (46.9) | 9.0% | 55,164 (48.2) | 3.6% | ||
| Female | 99,109 (52.3) | 6.5% | 39,935 (53.1) | 9.5% | 59,174 (51.8) | 4.4% | ||
| SES | .01 | 0.87 | ||||||
| < $30,000 NTD | 72,579 (38.3) | 6.3% | 28,780 (38.3) | 9.7% | 43,799 (38.3) | 4.1% | ||
| ≥ $30,000 NTD | 64,934 (34.3) | 6.0% | 25,508 (33.9) | 8.9% | 39,426 (34.5) | 4.0% | ||
| Others | 51,997 (27.4) | 6.1% | 20,884 (27.8) | 9.1% | 31,113 (27.2) | 8.2% | ||
| Major comorbidity | .08 | < .01 | ||||||
| No | 176,466 (93.1) | 6.1% | 69,702 (92.7) | 9.3% | 106,764 (93.4) | 4.0% | ||
| Yes | 13,044 (6.9) | 6.5% | 5,470 (7.3) | 8.6% | 7,574 (6.6) | 5.0% | ||
|
| ||||||||
| Physician age, Y | .25 | < .01 | ||||||
| ≤40 | 50,369 (26.6) | 5.1% | 13,556 (18.0) | 9.4% | 36,813 (32.2) | 3.5% | ||
| 40–59 | 108,827 (57.4) | 6.2% | 45,207 (60.1) | 9.1% | 63,620 (55.6) | 4.1% | ||
| ≥60 | 30,314 (16.0) | 7.7% | 16,409 (21.8) | 9.6% | 13,905 (12.2) | 5.6% | ||
| Physician sex | < .01 | < .01 | ||||||
| Male | 167,187 (88.2) | 6.4% | 68,746 (91.5) | 9.5% | 98,441 (86.1) | 4.3% | ||
| Female | 22,323 (11.8) | 3.8% | 6,426 (8.5) | 6.7% | 15,897 (13.9) | 2.6% | ||
| Physician specialty | < .01 | < .01 | ||||||
| Family medicine | 38,969 (20.6) | 3.8% | 16,185 (21.5) | 6.1% | 22,784 (19.9) | 2.1% | ||
| Internal medicine | 62,606 (33.0) | 3.3% | 20,806 (27.7) | 5.6% | 41,800 (36.6) | 2.2% | ||
| Otolaryngology | 21,511 (11.4) | 15.5% | 12,870 (17.1) | 18.4% | 8,641 (7.6) | 11.2% | ||
| Emergency | 35,567 (18.8) | 8.3% | 9,238 (12.3) | 15.0% | 26,329 (23.0) | 6.0% | ||
| Others | 30,857 (16.3) | 5.8% | 16,073 (21.4) | 6.6% | 14,784 (12.9) | 4.9% | ||
| Average monthly volume | < .01 | < .01 | ||||||
| Low | 62,536 (33.0) | 5.6% | 13,688 (18.2) | 11.9% | 48,848 (42.7) | 3.9% | ||
| Medium | 62,540 (33.0) | 5.9% | 27,475 (36.5) | 8.6% | 35,065 (30.7) | 3.8% | ||
| High | 64,434 (34.0) | 6.8% | 34,009 (45.2) | 8.8% | 30,425 (26.6) | 4.6% | ||
| Ownership of practice setting | .03 | < .01 | ||||||
| Private | 149,954 (79.1) | 6.7% | 68,272 (90.8) | 9.4% | 81,682 (71.4) | 4.5% | ||
| Public | 39,556 (20.9) | 4.0% | 6,900 (9.2) | 8.6% | 32,656 (28.6) | 3.0% | ||
| Accreditation level of practice setting | < .01 | < .01 | ||||||
| Medical center | 34,402 (18.2) | 5.2% | 6,935 (9.2) | 9.8% | 27,467 (24.0) | 4.0% | ||
| Regional/District hospital | 60,735 (32.0) | 4.8% | 14,972 (19.9) | 10.0% | 45,763 (40.0) | 3.0% | ||
| Clinics | 94,373 (49.8) | 7.4% | 53,265 (70.9) | 9.0% | 41,108 (36.0) | 5.2% | ||
| Urbanization of practice | .05 | .02 | ||||||
| Urban | 158,982 (83.9) | 6.0% | 59,423 (79.0) | 9.4% | 99,559 (87.1) | 4.0% | ||
| Non-urban | 30,528 (16.1) | 6.7% | 15,749 (21.0) | 8.9% | 14,779 (12.9) | 4.4% | ||
$30 NTD ≌ $1 US dollar.
Abbreviation: SES, socioeconomic status; P, P-value.
Patient and physician characteristics associated with antibiotic prescribing for dengue patients in outpatient settings, Taiwan, 2008–2015.
| Total | Pre-dengue confirmation | Post-dengue confirmation | ||||
|---|---|---|---|---|---|---|
| OR (95%CI) | AOR (95% CI) | OR (95%CI) | AOR (95% CI) | OR (95%CI) | AOR (95% CI) | |
|
| ||||||
| No | Ref | ref | ref | ref | ref | ref |
| Yes | 0.70 (0.64–0.76) | 0.67 (0.61–0.72) | 0.84 (0.77–0.93) | 0.82 (0.74–0.89) | 0.65 (0.57–0.73) | 0.59 (0.53–0.67) |
|
| ||||||
| Age, y | ||||||
| 18–45 | Ref | ref | ref | ref | ref | ref |
| 45–64 | 0.89 (0.86–0.93) | 0.89 (0.85–0.93) | 0.87 (0.82–0.92) | 0.89 (0.84–0.93) | 0.90 (0.85–0.95) | 0.88 (0.83–0.94) |
| ≥65 | 0.97 (0.90–1.03) | 0.99 (0.93–1.06) | 0.87 (0.80–0.94) | 0.90 (0.84–0.97) | 1.03 (0.93–1.13) | 1.05 (0.95–1.16) |
| Sex | ||||||
| Male | Ref | ref | ref | ref | ref | ref |
| Female | 1.13 (1.08–1.17) | 1.14 (1.10–1.18) | 1.06 (1.01–1.12) | 1.08 (1.02–1.13) | 1.21 (1.14–1.28) | 1.23 (1.16–1.31) |
| SES | ||||||
| < $30,000 NTD | Ref | ref | ref | ref | ref | ref |
| ≥ $30,000 NTD | 0.95 (0.91–0.99) | 0.98 (0.94–1.02) | 0.94 (0.89–1.00) | 0.97 (0.92–1.03) | 0.97 (0.91–1.03) | 0.99 (0.93–1.06) |
| Others | 0.99 (0.95–1.03) | 1.01 (0.97–1.06) | 0.97 (0.92–1.03) | 1.01 (0.95–1.07) | 1.00 (0.94–1.07) | 1.02 (0.95–1.09) |
| Major comorbidity | ||||||
| No | Ref | ref | ref | ref | ref | ref |
| Yes | 1.11 (1.03–1.19) | 1.15 (1.07–1.24) | 0.98 (0.89–1.08) | 1.03 (0.94–1.13) | 1.22 (1.10–1.36) | 1.27 (1.13–1.42) |
|
| ||||||
| Physician age, Y | ||||||
| ≤40 | Ref | ref | ref | ref | ref | ref |
| 40–59 | 0.96 (0.86–1.07) | 1.06 (0.95–1.18) | 0.89 (0.79–1.00) | 1.07 (0.94–1.21) | 1.05 (0.91–1.20) | 1.09 (0.95–1.25) |
| ≥60 | 1.23 (1.08–1.41) | 1.57 (1.36–1.82) | 1.03 (0.88–1.19) | 1.45 (1.24–1.70) | 1.53 (1.27–1.84) | 1.83 (1.50–2.24) |
| Physician sex | ||||||
| Male | Ref | ref | ref | ref | ref | ref |
| Female | 0.71 (0.61–0.82) | 0.87 (0.75–1.01) | 0.78 (0.66–0.92) | 0.90 (0.75–1.07) | 0.70 (0.58–0.84) | 0.88 (0.73–1.05) |
| Physician specialty | ||||||
| Family medicine | Ref | ref | ref | ref | ref | ref |
| Internal medicine | 0.83 (0.71–0.96) | 0.94 (0.81–1.11) | 0.94 (0.79–1.12) | 1.00 (0.83–1.20) | 0.92 (0.76–1.11) | 1.00 (0.82–1.22) |
| Otolaryngology | 3.38 (2.84–4.03) | 3.54 (2.94–4.25) | 3.01 (2.50–3.61) | 3.25 (2.68–3.93) | 4.12 (3.26–5.20) | 4.25 (3.33–5.41) |
| Emergency | 2.20 (1.90–2.54) | 3.15 (2.61–3.80) | 2.62 (2.19–3.13) | 2.99 (2.37–3.77) | 2.41 (2.00–2.89) | 3.32 (2.66–4.14) |
| Others | 1.11 (0.95–1.29) | 1.24 (1.06–1.44) | 1.00 (0.85–1.18) | 1.11 (0.94–1.32) | 1.55 (1.26–1.89) | 1.56 (1.28–1.92) |
| Average monthly volume | ||||||
| Low | Ref | ref | ref | ref | ref | ref |
| Medium | 1.05 (0.95–1.16) | 1.00 (0.89–1.12) | 0.80 (0.71–0.89) | 0.88 (0.78–1.01) | 1.16 (1.01–1.32) | 1.04 (0.89–1.22) |
| High | 1.10 (0.98–1.24) | 0.86 (0.75–1.00) | 0.81 (0.71–0.92) | 0.80 (0.68–0.94) | 1.19 (1.01–1.40) | 0.84 (0.69–1.02) |
| Ownership of practice setting | ||||||
| Private | Ref | ref | ref | ref | ref | ref |
| Public | 0.63 (0.56–0.71) | 0.80 (0.71–0.91) | 0.87 (0.75–1.00) | 0.91 (0.79–1.05) | 0.62 (0.54–0.71) | 0.82 (0.70–0.95) |
| Accreditation level of practice setting | ||||||
| Medical center | ref | ref | ref | ref | ref | ref |
| Regional/District hospital | 0.99 (0.87–1.13) | 1.03 (0.92–1.16) | 0.98 (0.84–1.14) | 1.07 (0.92–1.23) | 0.90 (0.77–1.05) | 0.95 (0.82–1.10) |
| Clinics | 1.32 (1.17–1.49) | 1.38 (1.20–1.59) | 0.98 (0.86–1.13) | 1.21 (1.02–1.44) | 1.33 (1.14–1.54) | 1.28 (1.07–1.54) |
| Urbanization of practice | ||||||
| Urban | ref | ref | ref | ref | ref | ref |
| Non-urban | 1.16 (1.03–1.30) | 1.10 (0.97–1.25) | 1.07 (0.94–1.22) | 1.06 (0.93–1.21) | 1.10 (0.96–1.27) | 1.08 (0.92–1.25) |
$30 NTD ≌ $1 US dollar.
Abbreviation: SES, socioeconomic status.
The top 5 antibiotics used in adult dengue patients.
| Outpatient Setting | Inpatient Setting | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-dengue confirmation | Post-dengue confirmation | Pre-dengue confirmation | Post-dengue confirmation | ||||||
| No. | Antibiotics | % | Antibiotics | % | Antibiotics | % | Antibiotics | % | |
| 1 | cefalexin | 29.9 | cefalexin | 27.9 | cefazolin | 38.1 | cefazolin | 34.3 | |
| 2 | cefradine | 14.2 | cefradine | 14.5 | ceftriaxone | 16.2 | cefuroxime | 13.8 | |
| 3 | clindamycin | 7.9 | cefazolin | 7.3 | levofloxacin | 15.2 | ceftriaxone | 13.7 | |
| 4 | cefadroxil | 5.8 | doxycycline | 6.3 | doxycycline | 15.0 | levofloxacin | 11.9 | |
| 5 | doxycycline | 4.8 | cefuroxime | 5.7 | cefuroxime | 10.9 | doxycycline | 8.9 | |
Inpatient antibiotic use for confirmed dengue by patient and physician characteristics, in pre- and post- dengue diagnosis periods, Taiwan, 2008–2015.
| Total | Pre-dengue confirmation | Post- dengue confirmation | ||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotics use | Antibiotics use | Antibiotics use | ||||||
| N (%) | % | N (%) | % | P | N (%) | % | P | |
|
|
|
|
|
|
|
| ||
|
| .50 | .30 | ||||||
| No | 2,703 (14.5) | 35.4% | 885 (53.1) | 53.1% | 1,854 (11.6) | 26.8% | ||
| Yes | 15,926 (85.5) | 29.2% | 2,015 (52.0) | 52.0% | 14,194 (88.4) | 25.9% | ||
|
| ||||||||
| Age, y | < .01 | < .01 | ||||||
| 18–45 | 5,418 (29.1) | 23.2% | 826 (46.2) | 46.2% | 4,661 (29.0) | 19.0% | ||
| 45–64 | 6,581 (35.3) | 25.3% | 998 (46.2) | 46.2% | 5,684 (35.4) | 21.6% | ||
| ≥65 | 6,630 (35.6) | 40.4% | 1,076 (62.6) | 62.6% | 5,703 (35.5) | 36.1% | ||
| Sex | < .01 | < .01 | ||||||
| Male | 8,845 (47.5) | 27.3% | 1,379 (48.0) | 48.0% | 7,630 (47.5) | 23.4% | ||
| Female | 9,784 (52.5) | 32.6% | 1,521 (56.2) | 56.2% | 8,418 (52.5) | 28.3% | ||
| SES | .04 | < .01 | ||||||
| < $30,000 NTD | 6,395 (34.3) | 28.3% | 993 (52.1) | 52.1% | 5,499 (34.3) | 24.0% | ||
| ≥ $30,000 NTD | 6,218 (33.4) | 28.4% | 885 (48.8) | 48.8% | 5,427 (33.8) | 25.1% | ||
| Others | 6,016 (32.3) | 33.6% | 1,022 (55.6) | 55.6% | 5,122 (31.9) | 29.1% | ||
| Major comorbidity | < .01 | < .01 | ||||||
| No | 16,903 (90.7) | 28.8% | 2,567 (50.5) | 50.5% | 14,594 (90.9) | 24.9% | ||
| Yes | 1,726 (9.3) | 42.4% | 333 (66.1) | 66.1% | 1,454 (9.1) | 36.7% | ||
|
| ||||||||
| Physician age, Y | .60 | < .01 | ||||||
| ≤40 | 7,243 (38.9) | 32.6% | 1,144 (51.8) | 51.8% | 6,099 (29.0) | 29.0% | ||
| 40–59 | 10,813 (58.0) | 28.8% | 1,675 (52.8) | 52.8% | 9,138 (24.4) | 24.4% | ||
| ≥60 | 573 (3.1) | 21.8% | 81 (48.1) | 48.1% | 492 (17.5) | 17.5% | ||
| Physician sex | .67 | .68 | ||||||
| Male | 16,251 (87.2) | 29.9% | 2,486 (52.4) | 52.4% | 13,765 (25.8) | 25.8% | ||
| Female | 2,378 (12.8) | 31.2% | 414 (51.7) | 51.7% | 1,964 (26.8) | 26.8% | ||
| Average monthly volume | < .01 | < .01 | ||||||
| Low | 6,369 (34.2) | 33.0% | 950 (57.7) | 57.7% | 5,419 (28.7) | 28.7% | ||
| Medium | 5,995 (32.2) | 25.9% | 1,078 (47.6) | 47.6% | 4,917 (21.1) | 21.1% | ||
| High | 6,265 (33.6) | 31.1% | 872 (52.3) | 52.3% | 5,393 (27.7) | 27.7% | ||
| Ownership of practice setting | .06 | < .01 | ||||||
| Private | 10,849 (58.2) | 28.8% | 1,944 (50.8) | 50.8% | 8,905 (24.0) | 24.0% | ||
| Public | 7,780 (41.8) | 31.9% | 956 (55.4) | 55.4% | 6,824 (28.6) | 28.6% | ||
| Accreditation level of practice setting | .74 | < .01 | ||||||
| Medical center | 5,803 (31.2) | 32.4% | 877 (54.0) | 54.0% | 4,926 (28.6) | 28.6% | ||
| Regional/District hospital | 12,826 (68.8) | 29.0% | 2,023 (51.6) | 51.6% | 10,803 (24.8) | 24.8% | ||
| Clinics | ||||||||
| Urbanization of practice | .05 | < .01 | ||||||
| Urban | 16,032 (86.1) | 30.3% | 2,238 (53.4) | 53.4% | 13,794 (26.5) | 26.5% | ||
| Non-urban | 2,597 (13.9) | 29.0% | 662 (48.8) | 48.8% | 1,935 (22.2) | 22.2% | ||
$30 NTD ≌ $1 US dollar.
Abbreviation: SES, socioeconomic status; P, P-value.
Patient and physician characteristics associated with antibiotic prescribing for dengue patients in inpatient setting, Taiwan, 2008–2015.
| Total | Pre-dengue confirmation | Post- dengue confirmation | ||||
|---|---|---|---|---|---|---|
| OR (95%CI) | AOR (95% CI) | OR (95%CI) | AOR (95% CI) | OR (95%CI) | AOR (95% CI) | |
|
| ||||||
| No | ref | ref | ref | ref | ref | ref |
| Yes | 0.80 (0.69–0.91) | 0.72 (0.62–0.84) | 1.00 (0.82–1.21) | 0.90 (0.75–1.09) | 0.96 (0.82–1.12) | 0.88 (0.74–1.04) |
|
| ||||||
| Age, y | ||||||
| 18–45 | ref | ref | ref | ref | ref | ref |
| 45–64 | 1.15 (1.08–1.22) | 1.12 (1.05–1.20) | 1.01 (0.85–1.19) | 0.98 (0.82–1.17) | 1.17 (1.09–1.27) | 1.14 (1.05–1.24) |
| ≥65 | 1.93 (1.76–2.12) | 1.88 (1.71–2.07) | 1.77 (1.44–2.19) | 1.76 (1.43–2.18) | 2.00 (1.80–2.23) | 1.90 (1.71–2.12) |
| Sex | ||||||
| Male | ref | ref | ref | ref | ref | ref |
| Female | 1.25 (1.19–1.32) | 1.24 (1.18–1.31) | 1.38 (1.20–1.58) | 1.38 (1.19–1.60) | 1.26 (1.18–1.33) | 1.25 (1.18–1.33) |
| SES | ||||||
| < $30,000 NTD | ref | ref | ref | ref | ref | ref |
| ≥ $30,000 NTD | 0.98 (0.92–1.04) | 0.94 (0.88–1.00) | 0.89 (0.75–1.05) | 0.85 (0.72–1.00) | 1.02 (0.95–1.09) | 0.97 (0.90–1.04) |
| Others | 1.18 (1.11–1.25) | 1.02 (0.96–1.08) | 1.06 (0.91–1.23) | 0.91 (0.78–1.06) | 1.21 (1.13–1.29) | 1.04 (0.97–1.12) |
| Major comorbidity | ||||||
| No | ref | ref | ref | ref | ref | ref |
| Yes | 1.53 (1.40–1.69) | 1.38 (1.25–1.53) | 1.57 (1.24–1.98) | 1.48 (1.17–1.88) | 1.51 (1.36–1.68) | 1.33 (1.19–1.48) |
|
| ||||||
| Physician age, Y | ||||||
| ≤40 | ref | ref | ref | ref | ref | ref |
| 40–59 | 0.98 (0.87–1.10) | 1.01 (0.89–1.14) | 1.16 (0.93–1.45) | 1.23 (0.98–1.55) | 0.99 (0.86–1.13) | 0.96 (0.83–1.11) |
| ≥60 | 0.71 (0.50–1.03) | 0.74 (0.52–1.06) | 0.97 (0.53–1.77) | 1.00 (0.53–1.88) | 0.67 (0.42–1.06) | 0.67 (0.43–1.05) |
| Physician sex | ||||||
| Male | ref | ref | ref | ref | ref | ref |
| Female | 0.92 (0.76–1.11) | 0.90 (0.73–1.10) | 0.97 (0.73–1.28) | 0.99 (0.74–1.32) | 0.95 (0.77–1.16) | 0.91 (0.73–1.14) |
| Average monthly volume | ||||||
| Low | ref | ref | ref | ref | ref | ref |
| Medium | 0.88 (0.78–1.00) | 0.90 (0.77–1.06) | 0.73 (0.60–0.89) | 0.73 (0.60–0.90) | 0.85 (0.73–0.98) | 0.88 (0.75–1.04) |
| High | 0.95 (0.81–1.11) | 1.02 (0.86–1.20) | 0.93 (0.72–1.18) | 0.93 (0.73–1.19) | 0.91 (0.76–1.08) | 0.97 (0.80–1.16) |
| Ownership of practice setting | ||||||
| Private | ref | ref | ref | ref | ref | ref |
| Public | 0.94 (0.81–1.08) | 0.95 (0.83–1.09) | 0.99 (0.80–1.24) | 0.99 (0.78–1.26) | 1.00 (0.84–1.18) | 0.98 (0.85–1.14) |
| Accreditation level of practice setting | ||||||
| Medical center | ref | ref | ref | ref | ref | ref |
| Regional/District hospital | 0.64 (0.56–0.73) | 0.65 (0.56–0.75) | 0.97 (0.78–1.21) | 1.03 (0.80–1.31) | 0.54 (0.47–0.63) | 0.56 (0.48–0.66) |
| Urbanization of practice | ||||||
| Urban | ref | ref | ref | ref | ref | ref |
| Non-urban | 0.96 (0.75–1.23) | 1.23 (0.98–1.55) | 1.02 (0.77–1.37) | 1.12 (0.81–1.55) | 0.80 (0.65–0.98) | 1.12 (0.90–1.40) |
$30 NTD ≌ $1 US dollar.
Abbreviation: SES, socioeconomic status; P, P-value.